| Literature DB >> 22860173 |
Che-Chuan Yang1, Shieh-Yueh Yang, Jen-Jie Chieh, Herng-Er Horng, Chin-Yih Hong, Hong-Chang Yang, K H Chen, B Y Shih, Ta-Fu Chen, Ming-Jang Chiu.
Abstract
Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ∼10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.Entities:
Keywords: Magnetic nanoparticles; immunomagnetic reduction; β-amyloid
Mesh：
Substances：
Year: 2011 PMID： 22860173 PMCID： PMC3369781 DOI： 10.1021/cn200028j
Source DB: PubMed Journal: ACS Chem Neurosci ISSN： 1948-7193 Impact factor: 4.418